Supplementary Table 7. Kaplan–Meier analysis of differential expressions of immune and stromal markers for RFS and OS in validation cohort (n=240)

Immune markers	Stratification	RFS			OS		
		mRFS (95% CI)	χ^2	*P*-value	mOS (95% CI)	χ^2	*P*-value
CD3	Low	15.96 (12.69–19.22)	11.19	<0.001	24.03 (20.30–27.76)	5.44	0.020
	High	23.05 (20.72–25.39)			29.31 (26.93–31.68)		
CD4	Low	14.31 (10.82–17.80)	17.05	<0.001	23.07 (18.80–27.34)	9.54	0.002
	High	22.47 (20.26–24.68)			28.78 (26.54–31.03)		
CD8	Low	18.24 (15.22–21.27)	6.59	0.010	25.80 (22.57–29.04)	4.12	0.042
	High	22.46 (19.95–24.96)			28.78 (26.23–31.33)		
Foxp3	Low	22.58 (20.00–25.16)	4.58	0.032	29.82 (27.14–32.50)	6.42	0.011
	High	18.78 (15.87–21.69)			25.10 (22.14–28.06)		
CD68	Low	22.21 (19.67–24.76)	3.63	0.057	29.44 (26.87–32.01)	4.13	0.042
	High	18.20 (15.36–21.04)			24.23 (21.17–27.29)		
CD66b	Low	22.16 (19.86–24.46)	8.47	0.004	29.15 (26.83–31.47)	8.55	0.003
	High	16.36 (13.13–19.59)			22.56 (18.88–26.24)		
Stroma	Dormant	27.49 (23.21–31.77)	37.41	<0.001	33.36 (29.52–37.20)	26.98	<0.001
	Fibrogenic	22.11 (18.50–25.72)			29.52 (25.77–33.27)		
	Inert	19.86 (16.22–23.50)			25.47 (21.61–29.34)		
	Fibrolytic	12.20 (9.37–15.03)			21.05 (16.92–25.18)		

CI, confidence interval; mRFS, median recurrence-free survival time; mOS, median overall survival time; OS, overall survival; RFS, recurrence-free survival.